Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.58 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8418979 | 0.93 | HPGD (0.56) | HPGDPOLBGSTP1GSTM2ALDH1A1 | |
| SCHEMBL22226687 | 0.90 | GSTP1 (0.58) | HPGDPOLBGSTP1GSTM2ALDH1A1 | |
| SCHEMBL8102330 | 0.87 | HPGD (0.60) | HPGDPOLBALDH1A1MAPTVCAM1 | |
| SCHEMBL14476018 | 0.87 | HPGD (0.67) | HPGDPOLBALDH1A1MAPTVCAM1 | |
| SCHEMBL1995617 | 0.86 | HPGD (0.59) | HPGDPOLBALDH1A1MAPTVCAM1 | |
| SCHEMBL23768982 | 0.84 | HPGD (0.63) | HPGDPOLBALDH1A1MAPTVCAM1 | |
| SCHEMBL21291391 | 0.83 | HPGD (0.61) | HPGDPOLBALDH1A1MAPTVCAM1 | |
| SCHEMBL5253794 | 0.81 | GSTP1 (0.57) | HPGDGSTP1GSTM2ALDH1A1MAPT | |
| SCHEMBL5917877 | 0.81 | HPGD (0.66) | HPGDPOLBALDH1A1MAPTVCAM1 | |
| SCHEMBL1390827 | 0.81 | ALDH1A1 (0.46) | HPGDPOLBGSTP1GSTM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007016610-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | HPGD 632/4885POLB 301/4885GSTP1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.